A Phase 1 interventional study of LEO 90100 aerosol foam and Dermoval®/Dermovate® in Psoriasis Vulgaris, sponsored by LEO Pharma. Completed at 1 site in France. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-05-09.
Sponsored by LEO Pharma · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing betamethasone dipropionate in Psoriasis — 1 open to participants now, 1 under way, 1 of them phase 3. betamethasone dipropionate · Psoriasis.
Among the 29 studies testing betamethasone dipropionate in Psoriasis, this one is the 24th largest by enrollment, is one of 3 that started in 2016, is one of 2 in phase 1, and was the 19th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →1 of the 29 studies testing betamethasone dipropionate in Psoriasis is open now, in 1 country. Recruiting first, the newest first:
Wake Forest University Health Sciences · Sites in United States
Ages 18+
By country, each count listing its studies:
betamethasone dipropionate: first FDA approval 1975 (DIPROSONE). What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 11 · Phase 4 7
First in 2004; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 224 across the 29 interventional studies. Of the 27 that completed or were terminated, 15 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 29 have an industry lead sponsor. The 10 most frequent:
LEO Pharma is the lead sponsor of 225 studies on the registry; 5 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 24 (75%) have results posted.
79 studies in Psoriasis by LEO Pharma: 1 open now, 2 under way, none of them phase 3. Of 77 finished, 36 (47%) have results posted.
Among the 79 studies in Psoriasis by LEO Pharma, this one is the 43rd largest by enrollment of the 71 interventional ones that give a count, is one of 8 that started in 2016, is one of 19 in phase 1, and was the 65th registered.
LEO Pharma’s Psoriasis studies by the year they started, since 2004.
1 of the studies testing betamethasone dipropionate in Psoriasis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05981118Phase 3Wake Forest University Health SciencesComparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant) | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies testing betamethasone dipropionate in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among LEO Pharma’s 79 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
Vasoconstriction study with LEO 90100
This study compares the pharmacodynamic activity of LEO 90100 with Dermovate cream, Diprosone ointment, Elocon cream, Locoid ointment and LEO 90100 vehicle using a human skin blanching test
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
LEO 90100 calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate) aerosol foam Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once.
Drug: LEO 90100 aerosol foam · Drug: Dermoval®/Dermovate® · Drug: Diprosone · Drug: Elocon · Drug: Locoid · Other: LEO 90100 foam vehicle
Dermoval®/Dermovate® (clobetasol propionate 0.05%) cream Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once.
Drug: LEO 90100 aerosol foam · Drug: Dermoval®/Dermovate® · Drug: Diprosone · Drug: Elocon · Drug: Locoid · Other: LEO 90100 foam vehicle
Diprosone® betamethasone 0.5 mg/g (as dipropionate) ointment Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once.
Drug: LEO 90100 aerosol foam · Drug: Dermoval®/Dermovate® · Drug: Diprosone · Drug: Elocon · Drug: Locoid · Other: LEO 90100 foam vehicle
Elocon® mometasone furoate 0.1% cream Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once.
Drug: LEO 90100 aerosol foam · Drug: Dermoval®/Dermovate® · Drug: Diprosone · Drug: Elocon · Drug: Locoid · Other: LEO 90100 foam vehicle
Locoid® hydrocortisone-17-butyrate 0.1% ointment Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once.
Drug: LEO 90100 aerosol foam · Drug: Dermoval®/Dermovate® · Drug: Diprosone · Drug: Elocon · Drug: Locoid · Other: LEO 90100 foam vehicle
LEO 90100 foam vehicle Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once.
Drug: LEO 90100 aerosol foam · Drug: Dermoval®/Dermovate® · Drug: Diprosone · Drug: Elocon · Drug: Locoid · Other: LEO 90100 foam vehicle
Mean of two visual skin blanching scores for each treatment measured 2 hours after 16 hours application under non-occlusive conditions
Time frame: 18 hours
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Dec 2016, a primary completion of Feb 2017 and a completion of Feb 2017. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: LEO 90100 · Betamethasone dipropionate · Mometasone Furoate · Hydrocortisone butyrate